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Abstract
Since its introduction into northern Europe in 2006, bluetongue has become a major threat to animal health. While
the efficacy of commercial vaccines has been clearly demonstrated in livestock, little is known regarding the effect
of maternal immunity on vaccinal efficacy. Here, we have investigated the duration and amplitude of colostral
antibody-induced immunity in calves born to dams vaccinated against bluetongue virus serotype 8 (BTV-8) and the
extent of colostral antibody-induced interference of vaccination in these calves. Twenty-two calf-cow pairs were
included in this survey. The median age at which calves became seronegative for BTV was 84 and 112 days as
assayed by seroneutralisation test (SNT) and VP7 BTV competitive ELISA (cELISA), respectively. At the mean age of
118 days, 13/22 calves were immunized with inactivated BTV-8 vaccine. In most calves vaccination elicited a weak
immune response, with seroconversion in only 3/13 calves. The amplitude of the humoral response to vaccination
was inversely proportional to the maternal antibody level prior to vaccination. Thus, the lack of response was
attributed to the persistence of virus-specific colostral antibodies that interfered with the induction of the immune
response. These data suggest that the recommended age for vaccination of calves born to vaccinated dams needs
to be adjusted in order to optimize vaccinal efficacy.
Introduction
Bluetongue (BT) is a non-contagious, arthropod-borne
viral disease affecting sheep, some species of wild rumi-
nants such as deer, and to a lesser extent, cattle and
goats. BT is a major concern in the international trade
of animals and animal products. Bluetongue virus (BTV),
the etiologic agent of the disease, is the type species of
the genus Orbivirus within the family Reoviridae.I ti s
transmitted almost exclusively by the bite of Culicoides
midges. Since 1998, five distinct serotypes of BTV (1, 2,
4, 9 and 16) have spread across southern and central
Europe [1,2]. In August 2006, a sixth serotype, BTV-8,
was first identified in northern Europe, from where it
quickly spread throughout the Netherlands, Belgium,
Luxembourg, Germany and northern France [3-6]. The
virus overwintered successfully in the same regions and
then spread to the United Kingdom, Denmark, Switzer-
land and the Czech Republic in 2007. The BTV-8 strain
circulating in northern Europe exhibits several unusual
properties, and notably its ability to cause disease and
mortality in cattle [2,7]. Mass vaccination campaigns
were quickly instituted to limit the spread and the dra-
matic socioeconomic consequences of the BT outbreak
in Europe. Commercially available inactivated vaccines
are now widely used to control BTV infection, and since
2008 vaccination of cattle is compulsory in some ende-
mic European countries. An issue that was not suffi-
ciently addressed prior to approval of inactivated BTV
vaccines was the optimum age at which calves born to
vaccinated dams should be vaccinated so as to avoid
colostral antibody-induced interference.
Newborn calves acquire pas s i v ei m m u n i t yf r o mt h e i r
dams by ingestion and absorption of antibodies present
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any medium, provided the original work is properly cited.in colostrum. The estimated duration and benefit of this
passively derived humoral immunity can vary greatly
depending on the colostrum production (quantity and
quality) and the quantity of antibody ingested and
absorbed. Maternally derived immunity can confer pro-
tection against a broad range of viral pathogens includ-
ing bovine herpesvirus-1 (BHV-1), bovine viral diarrhea
virus (BVDV) and bovine respiratory syncytial virus
(BRSV) [8-12]. Passive immunity frequently blocks the
production of serum antibodies when immunogens are
administered to calves with maternally derived antibo-
dies [13], even if in some cases immunogens can induce
immunological memory that is not susceptible to mater-
nal antibody regulation [14,15]. Also, vaccination against
BHV-1 and BRSV with modified live virus (MLV) vac-
cines can generate immune responses such as lympho-
cyte blastogenesis in calves with maternal antibodies to
BHV-1 and BRSV [16]. However, very few data are
available as regards the duration and effect of maternally
acquired immunity against BTV in calves that were born
to vaccinated cows. This prompted us to investigate:
(1) the time required for nursing beef calves to become
seronegative; (2) the effect of colostral antibodies on the
humoral response in calves after vaccination with an
inactivated BTV-8 vaccine.
Materials and methods
Animals
Twenty-two pairs of calves-pregnant cattle originating
from two distinct farms located in the north of France
(Tour and Font) were included in the survey. All cows
were vaccinated in May 2008 with an inactivated BTV-8
vaccine (Bovilis BTV8; Intervet) which was administered
subcutaneously according to the manufacturer’s instruc-
tions. The vaccinated cows were all seropositive for
BTV immediately prior to calving, as determined by a
VP7-specific BTV competition ELISA (cELISA) test
(data not shown). The cattle presented no clinical symp-
toms and no BTV RNA was detected by real-time PCR
(BTVM-Kit TAQVET™; LSI, France; data not shown).
The calves were born in October 2008 under standard
management conditions. Blood samples were collected
from calves at five time points; the first sample (S1) was
collected at approximately 48 days post-calving (range
36-60), S2 at 80 days (range 70-90), S3 at 111 days
(range 102-122), S4 at 139 days (range 127-150) and S5
at 202 days (range 189-207). Calves were tested for the
presence of BTV antibodies by cELISA and serum neu-
tralisation test (SNT). At a mean age of 118 days, 13/22
calves (3 from Tour and 10 from Font) were vaccinated
with the Bovilis BTV-8 inactivated vaccine. The vaccine
was administered as 2 subcutaneous injections 3 weeks
apart.
cELISA
BTV antibody levels were measured using the cELISA
ID Screen
® Bluetongue Competition assay (ID VET,
Montpellier, France) according to the manufacturer’s
instructions. Results are expressed as percentage of
negativity (PN) compared with the kit control and desig-
nated as positive, doubtful or negative according to the
cut-off values recommended by the manufacturer (PN ≤
35 is positive; 35 < PN ≤ 45 is doubtful; PN > 45 is
negative). Statistical analyses were performed using a
threshold value of 35 to discriminate between positive
(PN ≤ 35) and negative (PN > 35) BTV cELISA results
(see below).
Serum Neutralisation Test (SNT)
SNT was performed using the BTV-8 South African
reference strain and serotype-specific BTV-8 positive
control antisera. Briefly, 50 μL of sera were diluted (1:2
to 1:256) and titrated against 100 TCID50 (50 μL) of the
BTV-8 South African reference virus. Plates were incu-
bated for 1 h at 37°C and then 100 μL( 2×1 0
4)o fa
Vero (African green monkey kidney) cell suspension was
added per well. After incubation at 37°C for 5-7 days,
the wells were scored for cytopathic effect (CPE). The
neutralisation titre was defined as the dilution of serum
resulting in 50% neutralisation endpoint. Titres were
expressed as the log10 of the reciprocal endpoint serum
dilution. The positive-negative cut-off was 0.9 (titre <
0.9: negative; titre ≥ 0.9: positive).
Statistical analyses
The interval after birth when calves suckling seroposi-
tive cows became seronegative was determined using
the non-parametric survival Kaplan-Meier method. Sur-
vival analysis was used to address data describing how
long it takes for an event to occur. In this study, the
event is the fact that an animal becomes seronegative.
This event was not observed in some calves that were
still seropositive prior to vaccination: these were treated
as censored observations. Independent survival analyses
were conducted using the cELISA and SNT results.
A Kappa value was computed to determine the
agreement between cELISA and SNT in sera from
non-vaccinated animals (sera from vaccinated animals col-
lected before the vaccination date was also included). Kappa
values were interpreted according to Dohoo et al. [17].
The success of BTV vaccination was defined on the
basis of cELISA performed on samples collected three
months after the first vaccination. Analysis of variance
(ANOVA) was used to assess the existence of a relation-
ship between vaccination success and cELISA response
at S1, S2 and S3. A receiver operating characteristic
(ROC) analysis [18] was then conducted to model the
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cELISA response at S3. The cELISA cut-off resulting in
optimal predictions of vaccination success was deter-
mined. In order to establish the relation between age at
vaccination and vaccination success, we used the pre-
ceding cELISA cut-off to study the time interval until
cELISA rises above this value (corresponding to a nega-
tive status relatively to this cut-off). The Kaplan-Meier
survival analysis method was used to compute the age
at which vaccination would succeed in 50% of calves.
All statistical analysis and graphs were performed with
R [19].
Results
Correlation between SNT and ELISA
All 22 colostrum-fed calves were seropositive for BTV at
the first sampling, as determined by both SNT and
cELISA (i.e. S1, 36-60 day old calves). Twenty two pairs
of results were used to compare cELISA and SNT agree-
ment in calves before vaccination (Table 1); the overall
kappa value (0.49; 95% confidence interval [CI]: 0.3-0.7)
indicated a moderate agreement between the tests. Con-
cordance was higher in BTV positive serums as shown
in Figure 1. The result was confirmed by kappa esti-
mates computed at each time point before vaccination.
At S1 the agreement was perfect, as all animals were
positive using both tests. The agreement was poor at S2
(0.07; 95% CI: -0.2-0.3) and fair at S3 (0.24; 95%
CI: -0.4-0.9).
Estimated time to seronegative status using survival
analysis
Kaplan Meier survival curves showed that the apparent
interval after birth required for loss of passively acquired
antibodies depended upon the serological test used, and
was found to be earlier by SNT (Figure 2). The median
time after birth when calves born to seropositive cows
become seronegative was 112 days by cELISA (range 70
to 173) and 84 days by SNT (range 70 to 113 days).
Antibody response to BTV vaccination
Table 2 shows the cELISA PN for each vaccinated calf
at each interval after initial vaccination including the
serological status at S5 (202 day old calves). The data
shows three different types of response following
vaccination: non-responders (BTV cELISA PN higher
than before vaccination), mild responders (decrease in
BTV cELISA level compared with the level before vacci-
nation but without seroconversion) and strong respon-
ders (seroconversion after vaccination) (Table 2 and
Figure 3). In sample 1 (S1, mean age of 48 days), the
BTV antibody level was strong for all animals regardless
of group response and, therefore, ANOVA results were
Table 1 BTV antibody detection in serum samples from
non-vaccinated calves using cELISA and SNT
cELISA
Positive Negative Total
SNT Positive 17 0 17
Negative 3 2 5
Total 20 2 22
Figure 1 cELISA and SNT results box-plots in non-vaccinated
calves (line indicates median value, box indicates interquartile
range and bars indicate range).
Figure 2 Kaplan-Meier survival curves for time to BTV maternal
antibodies seronegativation in 22 calves tested with cELISA
and SN tests.
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Population N# S1 (48 d) S2 (80 d) S3 (111 d) S4 (139 d) S5 (202 d) Seroconversion status
a
Font 1 6 5 8 70 126 Neg
2 6 14 41 76 114 Neg
3 7 108 119 89 15 Pos
4 5 8 44 95 115 Neg
5 5 7 25 92 129 Neg
6 4 8 16 96 111 Neg
7 5 6 76 97 115 Neg
8 6 23 75 99 97 Neg
9 6 114 117 113 19 Pos
10 11 90 103 110 9 Pos
Tour A 7 17 62 78 43 Dbt
B 8 18 57 84 45 Neg
C 10 23 72 93 70 Neg
Total 8 (6-11) 104 (90-114) 113 (103-119) 104 (89-113) 14 (9-19) Pos (3/13)
6 (5-10) 13 (5-23) 48 (8-76) 88 (70-99) 96 (43-129) Neg or Dbt (10/13)
Strong responders 6-11 90-114 103-119 89-113 < 19 Pos (3/3)
Mild responders 7-10 17-23 57-72 78-93 43-70 Pos (0/3)
Non responders 5-6 5-24 8-76 70-99 > 96 Pos (0/7)
PN ≤ 35 is positive (pos); 35 < PN ≤ 45 is doubtful (dbt); PN > 45 is negative. The mean age of the calves is given in days (d) in parenthesis for each sample (S).
Calves were vaccinated at the mean age of 118 days (i.e. between S3 and 4).
Figure 3 Kinetic of BTV antibody level in vaccinated calves as measured by VP7 cELISA. Results are expressed as mean of percentage of
negativity (PN). A threshold value of 35 was defined to discriminate between positive (PN ≤ 35) and negative (PN > 45) cELISA results. Animals
were sampled five times post-calving (S1 to 5). The mean age of the calves is given in days (d) in parenthesis for each sample. Calves were
vaccinated at the mean age of 118 days (i.e. between S3 and 4). The group of calves that become seropositive after vaccination (strong
responders) are indicated in dashed line. Mild and non responders groups are labeled using doted and plain line respectively.
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between the response after vaccination and the cELISA
levels in the three groups at S2 (mean age of 80 days)
and S3 (mean age of 111 days) (p < 0.001). Indeed, at
S2, while mild and non-responders remained BTV sero-
positive with cELISA values ranging from 5 to 23, all
future responders already showed antibody levels
far below the cut-off limit of the test (Table 2 and
Figure 3). This trend was also confirmed immediately
before vaccination, at S3, with the group of responders
displaying cELISA PN > 103 whereas the antibody level
in poor and non-responders was PN < 76 (Figure 3).
cELISA level and vaccination success
After being shown to be inversely related to the
humoral response elicited by vaccination, cELISA titres
immediately prior to vaccination (S3) were used for
ROC analysis. A sensitivity and specificity of 100%
were obtained with cELISA cut-off values between 76
and 103.
To establish the relation between age at vaccination
and vaccination success, we studied the time interval
until cELISA becomes > 76 or > 103. As 6 days elapsed
between the third sampling date and the date of vacci-
nation, 6 days were added to these time intervals. The
resulting time intervals were shorter with the 76 cELISA
cut-off value than with the 103 cut-off value, as shown
in Figure 4. Median time for the 76 cut-off was
148 days (range 76 to 188 days). For the 103 cut-off
v a l u em e d i a nt i m ew a s1 8 0d a y s( r a n g e7 6t o1 9 7
days). These results indicate that in this animal sample
vaccination would have succeeded in 50% of the
animals, if they had been vaccinated between 148 and
180 days of age.
Discussion
Following the 2006 outbreak of BTV-8 in livestock in
northern Europe, BT has become a major concern in
animal health and trade. Vaccine manufacturers rapidly
provided efficacious and safe inactivated BTV-8 vaccines
that are now widely and successfully used throughout
Europe to control BTV infection [20,21]. However,
extensive studies have not been performed to evaluate
the effects of passive immunity in calves born to immu-
nized dams on the humoral response to BTV-8 immuni-
zation. In this survey, we followed the kinetics of loss of
BTV-8 specific colostral antibodies in calves born to
vaccinated dams using SNT and cELISA assays. Com-
parison of the antibody levels observed in these two
tests showed only a moderate agreement, likely reflect-
ing the fact that cELISA and SNT measure distinct anti-
body populations: the SNT titre declined more quickly
than the cELISA titre, and the kappa value was lower
than the overall kappa at the second sampling date (S2)
while it improved at the third sampling date (S3) when
the ELISA values had increased.
Recently, Oura et al. found that 22/22 lambs fed with
maternal colostrum from ewes vaccinated with the
Intervet Bovilis BTV-8 inactivated vaccine had protec-
tive neutralising antibodies at 10 weeks of age and 14/
22 (64%) at 14 weeks of age [22]. The persistence of
neutralising antibodies appears slightly longer than in
our study (84 days by SNT), possibly due to species dif-
ferences or study design. Following challenge with BTV-
8 at 13 to 14 weeks of age, all lambs were protected
from clinical disease and only 5/22 showed transitory
BTV RNA. These data show that maternally acquired
antibodies directed against BTV can confer long-lasting
protection against BTV infection. However, in another
study, the duration of protection may well have been
shorter, as no neutralising antibodies were found in
calves born from BTV-2 vaccinated dams after 39 days
of age [23]. It should be noted that several parameters
could affect the duration of colostral antibodies, includ-
ing the type of vaccine, the quantity of antibodies con-
sumed and absorbed from the colostrum, and the rate
of decay.
To determine the optimal age for vaccination of
calves, it is crucial to know at what time colostral anti-
bodies will have sufficiently waned so as not to interfere
with the vaccine. Currently, the recommended age for
vaccination of calves with inactivated BTV-8 vaccines
varies from 1 to 3 months, depending on the vaccine
manufacturer. However, these recommendations have
not been based on extensive study, especially on the
impact of colostral antibodies on the vaccinal response.
Figure 4 Vaccination success probability using two cut-off
cELISA values in 22 calves.
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nated animals with neutralising antibodies are generally
protected against infection, but that not all animals
without neutralising antibodies are fully susceptible
[21,22,24]. In the present study, vaccination of colos-
trum-fed calves with an inactivated viral vaccine poorly
induce anti-BTV humoral immunity in most cases
(Table 2 and Figure 3). From the data, it appears that
antibody levels measured by cELISA are more predictive
of vaccinal responsiveness than SNT. Indeed, a few days
before vaccination, all strong responders to vaccination
displayed cELISA-based PN ≥ 103, while the group of
non-responders exhibited mixed positive and negative
values, but all with PN < 76. Using SNT, both respon-
ders and non-responders showed BTV antibody titres
below the detection limit, precluding distinction
between the two groups. Moreover, by combining the
survival analysis of the BTV colostral antibodies and
the responsiveness to vaccination, we could estimate the
time required to achieve a vaccination success rate of
50% as falling between 148 and 180 days of age, depend-
ing on the cELISA cut-off used; the maximum vaccina-
tion success probability would be reached at around
7 months. Due to the small number of animals involved
in this survey, these results need to be confirmed and
refined in a larger cohort. However, this predictive value
confirms the apparent long-lasting presence of a protec-
tive humoral immunity against BTV in calves.
It is of critical importance to assure a shift from mater-
nal to vaccination protection without any gap in protec-
tion. Even though maternally-derived immunity may
block the antibody response in calves, anti-viral vaccina-
tion at the earliest possible time may be desirable, as
many calves acquire insufficient levels of maternal
antibodies [25]. Such calves should therefore respond to
vaccination, which raises the issue of the difficulty in
designing and implementing a universally successful
vaccination program. Since it is not conceivable to mea-
sure colostral antibodies before immunization, in order
to address the high levels of interference produced from
colostral antibodies, it may be wise to propose that:
(i) during periods of vector activity (May-October) and
potential virus circulation, calves born to vaccinated
dams should be vaccinated on two occasions, before
three months and then once again around the age of six
months in order to ensure maximal protection and pro-
vide vaccinal coverage for cases of poor colostrum intake
or inefficient vaccination of the dams; (ii) outside these
periods, in the absence of BTV circulation, it seems
unnecessary to vaccinate before weaning as maternally-
derived immunity prevents the humoral response to
vaccination, and vaccination around 5-6 months should
be adequate. Further investigations on this issue could
help to address the revision of current recommendations.
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